Oncolytics Biotech (ONCY) Income from Non-Controlling Interests (2009 - 2018)

Oncolytics Biotech (ONCY) has reported Income from Non-Controlling Interests for 5 consecutive years, with $382275.0 the latest figure, recorded in Q4 2018.

• On a quarterly basis, Income from Non-Controlling Interests rose 144.66% year-over-year to $382275.0 in Q4 2018; TTM through Dec 2018 was $3.5 million, a 59.83% decrease from a year earlier, with the FY2010 full-year figure at $8.4 million, up 1890.27% from the prior year.
• Income from Non-Controlling Interests was $382275.0 for Q4 2018 at Oncolytics Biotech, up from $156250.0 in the prior quarter.
• Over five years, Income from Non-Controlling Interests peaked at $382275.0 in Q4 2018 and troughed at $109641.0 in Q4 2016.
• A 3-year average of $216055.3 and a median of $156250.0 in 2017 frame the typical range for Income from Non-Controlling Interests.
• Across the five-year window, Income from Non-Controlling Interests soared 42.51% in 2017 and jumped 144.66% in 2018, its largest moves.
• Over 3 years, Income from Non-Controlling Interests stood at $109641.0 in 2016, then soared by 42.51% to $156250.0 in 2017, then jumped by 144.66% to $382275.0 in 2018.
• The last three Income from Non-Controlling Interests figures came in at $382275.0 (Q4 2018), $156250.0 (Q4 2017), and $109641.0 (Q4 2016), per Business Quant data.